Meanwhile, Covaxin’s developers on Wednesday also announced it has shown an overall interim clinical efficacy of 78% and a 100% efficacy against COVID-19
The Indian Council for Medical Research (ICMR) on Wednesday said that Covaxin, the indigenous vaccine against COVID-19 manufactured by Bharat Biotech can neutralize multiple strains and the double strain of COVID-19. Covaxin is one of the two vaccines being used in India’s vaccination drive
“ICMR study shows Covaxin neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR tweeted.
ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA @DeptHealthRes #IndiaFightsCOVID19 #LargestVaccineDrive pic.twitter.com/syv5T8eHuR
— ICMR (@ICMRDELHI) April 21, 2021
ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ), and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralization potential of Covaxin against the UK variant and Brazil variant, the top health research body said.
Also Read: Oxygen Leak From Tanker Outside Nashik Hospital Causes 22 Deaths
ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated.
Meanwhile, Covaxin’s developers on Wednesday also announced it has shown an overall interim clinical efficacy of 78% and a 100% efficacy against COVID-19. The Covaxin developers said that the safety and efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
“Efficacy against SARS-Cov-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. Covaxin is now a global innovator vaccine derived from Research and Development from India. The efficacy data against severe covid-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively,”
dR. kRISHNA eLLA, MANAGING DIRECTOR, BHARAT BIOTECH
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
